{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:53:09Z","timestamp":1791190389387,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MRC"},{"name":"Centre for Cognitive Neuroscience (Eli Lilly)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.neuropharm.2012.02.023","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T19:30:21Z","timestamp":1331926221000},"page":"114-121","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist\/mGlu3 antagonist"],"prefix":"10.1016","volume":"66","author":[{"given":"Lydia","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ceolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Monn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Collingridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuner","family":"Bortolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.02.023_bib1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jneumeth.2006.12.018","article-title":"Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions","volume":"162","author":"Anderson","year":"2007","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0028-3908(98)00091-4","article-title":"Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes","volume":"37","author":"Brabet","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00004647-200109000-00001","article-title":"Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs","volume":"21","author":"Bruno","year":"2001","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","article-title":"The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats","volume":"291","author":"Cartmell","year":"1999","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s002130050072","article-title":"Attenuation of specific PCP-evoked behaviors by the potent mGlu2\/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine","volume":"148","author":"Cartmell","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0014-2999(00)00423-4","article-title":"The mGlu(2\/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing","volume":"400","author":"Cartmell","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1471-4159.2000.0750889.x","article-title":"Regulation of neurotransmitter release by metabotropic glutamate receptors","volume":"75","author":"Cartmell","year":"2000","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib9","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1523\/JNEUROSCI.0418-11.2011","article-title":"Study of novel selective mGlu2 agonist in the temporo-ammonic input to CA1 neurons reveals reduced mGlu2 receptor expression in a Wistar substrain with an anxiety-like phenotype","volume":"31","author":"Ceolin","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/138161211795049570","article-title":"Targeting of metabotropic glutamate receptors for the treatment of schizophrenia","volume":"17","author":"Chaki","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib11","article-title":"Metabotropic glutamate receptors and the control of chronic pain","author":"Chiechio","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib12","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1021\/jm040222y","article-title":"Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist","volume":"48","author":"Dominguez","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib13","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1113\/jphysiol.1995.sp020697","article-title":"The perforant path projection to hippocampal area CA1 in the rat hippocampal-entorhinal cortex combined slice","volume":"484","author":"Empson","year":"1995","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.108.136861","article-title":"Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (\u2212)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)","volume":"326","author":"Fell","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.105.091074","article-title":"A\u00a0selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2\/3 receptor agonist in mouse models predictive of antipsychotic activity","volume":"315","author":"Galici","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behavior models of the mechanisms underlying antipsychotic atypicality","volume":"27","author":"Geyer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00213-003-1444-8","article-title":"Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans","volume":"168","author":"Grillon","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2007.12.057","article-title":"Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition","volume":"1197","author":"Gu","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib20","first-page":"27","article-title":"Pharmacological characterization of the group II metabotropic glutamate receptors in the Temporoammonic pathway of the hippocampus","volume":"9","author":"Hanna","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/366687a0","article-title":"Role of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb","volume":"366","author":"Hayashi","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3565(24)37253-2","article-title":"Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors","volume":"284","author":"Helton","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0006-8993(99)01065-3","article-title":"Phosphoinositide hydrolysis in\u00a0vivo with group I metabotropic glutamate receptor agonists","volume":"821","author":"Johnson","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0028-3908(00)00118-0","article-title":"Activity-dependent presynaptic autoinhibition by group II metabotropic glutamate receptors at the perforant path inputs to the dentate gyrus and CA1","volume":"40","author":"Kew","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","article-title":"Ionotropic and metabotropic glutamate receptor structure and pharmacology","volume":"179","author":"Kew","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0028-3908(02)00084-9","article-title":"Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2\u00a0\u2212\/\u2212 mice","volume":"43","author":"Kew","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(97)00191-3","article-title":"LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors","volume":"37","author":"Kingston","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00213-004-2098-x","article-title":"Anxiolytic-like activity of the mGLU2\/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice","volume":"179","author":"Linden","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib30","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/jm060917u","article-title":"Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (\u2212)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2\/3 receptors","volume":"50","author":"Monn","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1021\/jm980616n","volume":"42","author":"Monn","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/jm9606756","volume":"40","author":"Monn","year":"1997","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2010.01.030","article-title":"Group II metabotropic glutamate receptors (mGlu2\/3) in drug addiction","volume":"639","author":"Moussawi","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-0102(97)00120-X","article-title":"Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody","volume":"30","author":"Ohishi","year":"1998","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/jm970497w","article-title":"2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution","volume":"41","author":"Ornstein","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0306-4522(95)00533-1","article-title":"The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations","volume":"71","author":"Petralia","year":"1996","journal-title":"Neuroscience"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2012.02.023_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neuropharm.2005.05.009","article-title":"Group II and III mGluRs-mediated presynaptic inhibition of EPSCs recorded from hippocampal interneurons of CA1 stratum lacunosum moleculare","volume":"49","author":"Price","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cne.20538","volume":"487","author":"Richards","year":"2005","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-0173(86)90002-0","article-title":"Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis","volume":"396","author":"Robinson","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","article-title":"In\u00a0vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders","volume":"193","author":"Rorick-Kehn","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib45","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0028-3908(99)00092-1","article-title":"Pharmacological agents acting at subtypes of metabotropic glutamate receptors","volume":"38","author":"Schoepp","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib46","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1523\/JNEUROSCI.17-19-07503.1997","article-title":"Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus","volume":"17","author":"Shigemoto","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/7854_2010_36","article-title":"Metabotropic glutamate receptors: their therapeutic potential in anxiety","volume":"2","author":"Spooren","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib48","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(00)00269-7","article-title":"Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice","volume":"397","author":"Spooren","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.023_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0306-4522(01)00305-0","article-title":"Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites","volume":"106","author":"Tamaru","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib50","series-title":"The Rat Nervous System","first-page":"637","article-title":"Studies on the structure of the cerebral cortex. II. Continuation of the study of the ammonic system","author":"Witter","year":"2004"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-007-0974-x","article-title":"The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2\/3 agonist, LY379268, in mouse models predictive of antipsychotic activity","volume":"196","author":"Woolley","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.02.023_bib52","article-title":"CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [(3)H]LY459477 autoradiography","author":"Wright","year":"2012","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T10:47:44Z","timestamp":1742726864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":52,"alternative-id":["S0028390812000858"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.02.023","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}